THE USE OF PLATELET-RICH AUTOPLASMA IN THE TREATMENT OF PATIENTS WITH PYOINFLAMMATORY DISEASES OF SOFT TISSUES, BONES AND JOINTS

The advances of modern medicine are largely determined by the development and introduction of new technologies, which change the traditional understanding of treatment options. One of the most promising areas of scientific research, of course, is cell technologies. As for pyoinflammatory diseases of soft tissues, bones and joints it’s necessary to search for ways of stimulating angio - and osteogenesis in conditions of severe degradation of extracellular matrix and cell pool does not provide a favorable microenvironment for injected active cells. Hence, we can observe different performance of the methods based on the introduction of allo- or autologous cells and tissues from different patients associated with chronic inflammation. The solution seems to involve the drugs and methods which prepare the connective tissue due to remodulation of its structure, increase of hydrophilism, saturation of the growth factors necessary for the successful functioning of the cells. Such influence is sometimes ample for the achievement of the expressed clinical effect. The group of multimodal methods can reasonably be attributed to the treatment with platelet-rich plasma (PRP, PRP). Having been confirmed by numerous experimental and clinical studies, the biological effects of PRP can be considered such therapy as one of the most promising and not completely studied treatments.